Answers are grounded in this paper and cite their sources.
BACKGROUND: DNA methylation biomarkers have demonstrated promise as potential clinical biomarkers for improved detection and risk stratification of prostate cancer (PCa). Despite this, only sparse genome-scale, sequencing-based DNA methylation data are available in the early PCa setting. The EPIGEN-Prostate study aims to identify novel cell-free DNA methylation biomarkers from blood and multi-omic biomarkers from prostate tissue for detecting clinically significant PCa (csPCa). STUDY DESIGN: EPIGEN-Prostate is a multi-centre, prospective, longitudinal cohort study of patients undergoing investigation for potential PCa, with a biomarker discovery-focused design. The primary objective of this study is to characterise novel cell-free DNA-based molecular biomarkers for non-invasive PCa detection and risk stratification. Secondary objectives include the development of multi-omic risk classifiers to predict disease progression and treatment response. ENDPOINTS: The primary endpoint is the presence or absence of csPCa, defined here as International Society of Urological Pathology grade group ≥2. Secondary endpoints will include disease stage at presentation, disease recurrence following curative treatment, metastasis-free survival, and overall survival. PATIENTS AND METHODS: Individuals aged ≥18 years, scheduled to undergo prostate biopsy, and able to provide informed consent are eligible to participate. Blood samples will be prospectively collected before prostate biopsy, and prostate biopsy tissue will be retrieved for analysis after regular processing. Participants proceeding to radical prostatectomy may contribute surgical tissue and serial postoperative blood samples. Pre-biopsy plasma and matched prostate tissue samples will undergo genome-wide DNA methylation profiling using reduced representation bisulfite sequencing approaches. Tissue samples will also undergo RNA sequencing and genetic profiling. Clinical outcomes will be collected for up to 15 years. Biomarker discovery and validation will integrate molecular and clinical data using nested case-control analyses for each objective. TRIAL REGISTRATION: Not applicable. Human ethical approval was obtained via the New Zealand Health and Disability Ethics Committee - Southern (HDEC 21/STH/184).
No takes yet. Share an insight, caveat, or question.
Smith et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: